BUSINESS Alembic Pharmaceuticals receives USFDA approval for Levothyroxine Sodium Tablets May 22, 2026
Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution Dec 4, 2024
Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules Nov 11, 2024
Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY Nov 7, 2024
Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride Extended-Release capsules Oct 20, 2024
Alembic Pharmaceuticals hits 52-week high as its oncology formulations unit successfully completes USFDA inspection Oct 9, 2024
Alembic Pharmaceuticals successfully completes USFDA inspection at its Oncology Formulation Facility Oct 9, 2024
Alembic Pharmaceuticals shares surge 3% after receiving USFDA final approval for Lamotrigine Extended-Release Tablets Oct 3, 2024